(GH) Guardant Health - Overview

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US40131M1099

Stock: Cancer Tests, Blood Tests, Tissue Tests, Data Services

Total Rating 45
Risk 39
Buy Signal -0.30
Diagnostics & Research +3.7
Health Care Services +7.1
Market Cap: 11,870m
Avg Trading Vol: 176M USD
ATR: 5.98%
Peers RS (IBD): 88.7
Risk 5d forecast
Volatility 63.4%
Relative Tail Risk -10.7%
Reward TTM
Sharpe Ratio 1.47
Alpha 121.19
Character TTM
Beta 1.131
Beta Downside 0.918
Drawdowns 3y
Max DD 59.79%
CAGR/Max DD 0.83

EPS (Earnings per Share)

EPS (Earnings per Share) of GH over the last years for every Quarter: "2021-03": -1.09, "2021-06": -0.96, "2021-09": -1.06, "2021-12": -0.89, "2022-03": -1.21, "2022-06": -1.27, "2022-09": -1.41, "2022-12": -1.36, "2023-03": -1.3, "2023-06": -0.67, "2023-09": -0.73, "2023-12": -0.85, "2024-03": -0.94, "2024-06": -0.84, "2024-09": -0.88, "2024-12": -0.62, "2025-03": -0.49, "2025-06": -0.44, "2025-09": -0.39, "2025-12": -0.5,
EPS CAGR: 39.62%
EPS Trend: 88.8%
Last SUE: 1.19
Qual. Beats: 4

Revenue

Revenue of GH over the last years for every Quarter: 2021-03: 78.665, 2021-06: 92.101, 2021-09: 94.779, 2021-12: 108.108, 2022-03: 96.099, 2022-06: 109.144, 2022-09: 117.404, 2022-12: 126.891, 2023-03: 128.714, 2023-06: 137.15, 2023-09: 143.03, 2023-12: 155.054, 2024-03: 168.491, 2024-06: 177.235, 2024-09: 191.476, 2024-12: 201.814, 2025-03: 203.471, 2025-06: 232.088, 2025-09: 265.196, 2025-12: 281.266,
Rev. CAGR: 33.16%
Rev. Trend: 99.5%
Last SUE: 0.95
Qual. Beats: 7

Description: GH Guardant Health March 04, 2026

Guardant Health, Inc. (GH) is a precision oncology company. It develops and provides blood and tissue tests for cancer detection and monitoring.

The companys product portfolio includes liquid biopsy tests like Guardant360 CDx and Guardant360 Liquid for tumor mutation profiling. It also offers the Guardant Reveal test for molecular-level cancer detection and the Guardant360 Tissue test for comprehensive tumor profiling.

Guardant Health provides the Shield blood test for colorectal cancer screening. Colorectal cancer screening is a significant market within diagnostics, focusing on early detection to improve patient outcomes.

Additional offerings include the GuardantINFINITY and GuardantOMNI tests for advanced cancer research and therapy development. The company also provides GuardantINFORM for longitudinal tumor evolution insights and GuardantConnect, a software solution connecting patients with clinical studies.

Guardant Healths Smart Platform delivers multiomic insights. The company also offers development services, including companion diagnostic development and regulatory support. Companion diagnostics are critical for personalized medicine, linking specific therapies to diagnostic test results.

For more detailed financial analysis and valuation metrics, consider exploring ValueRay.

Headlines to watch out for

  • Guardant360 sales drive revenue growth
  • Shield colorectal cancer screening adoption crucial
  • Reimbursement policies impact test profitability
  • Clinical trial success expands market opportunities

Piotroski VR‑10 (Strict, 0-10) 2.5

Net Income: -416.3m TTM > 0 and > 6% of Revenue
FCF/TA: -0.11 > 0.02 and ΔFCF/TA 7.54 > 1.0
NWC/Revenue: 118.5% < 20% (prev 112.2%; Δ 6.21% < -1%)
CFO/TA -0.09 > 3% & CFO -172.5m > Net Income -416.3m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 4.84 > 1.5 & < 3
Outstanding Shares: last quarter (128.7m) vs 12m ago 3.96% < -2%
Gross Margin: 64.46% > 18% (prev 0.61%; Δ 6.39k% > 0.5%)
Asset Turnover: 56.13% > 50% (prev 49.74%; Δ 6.38% > 0%)
Interest Coverage Ratio: -106.1 > 6 (EBITDA TTM -373.9m / Interest Expense TTM 3.90m)

Altman Z'' -4.14

A: 0.58 (Total Current Assets 1.47b - Total Current Liabilities 302.7m) / Total Assets 2.01b
B: -1.49 (Retained Earnings -2.99b / Total Assets 2.01b)
C: -0.24 (EBIT TTM -413.6m / Avg Total Assets 1.75b)
D: -1.42 (Book Value of Equity -3.00b / Total Liabilities 2.11b)
Altman-Z'' Score: -4.14 = D

Beneish M -2.91

DSRI: 0.94 (Receivables 137.8m/110.3m, Revenue 982.0m/739.0m)
GMI: 0.94 (GM 64.46% / 60.79%)
AQI: 1.18 (AQ_t 0.12 / AQ_t-1 0.10)
SGI: 1.33 (Revenue 982.0m / 739.0m)
TATA: -0.12 (NI -416.3m - CFO -172.5m) / TA 2.01b)
Beneish M-Score: -2.91 (Cap -4..+1) = A

What is the price of GH shares?

As of March 14, 2026, the stock is trading at USD 88.03 with a total of 1,572,908 shares traded.
Over the past week, the price has changed by -6.26%, over one month by -18.46%, over three months by -16.73% and over the past year by +110.36%.

Is GH a buy, sell or hold?

Guardant Health has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy GH.
  • StrongBuy: 15
  • Buy: 6
  • Hold: 3
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the GH price?

Issuer Target Up/Down from current
Wallstreet Target Price 132.6 50.6%
Analysts Target Price 132.6 50.6%

GH Fundamental Data Overview March 12, 2026

P/S = 12.0869
P/B = 55.6696
Revenue TTM = 982.0m USD
EBIT TTM = -413.6m USD
EBITDA TTM = -373.9m USD
Long Term Debt = 1.50b USD (from longTermDebt, last quarter)
Short Term Debt = 26.4m USD (from shortTermDebt, two quarters ago)
Debt = 1.68b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.30b USD (from netDebt column, last quarter)
Enterprise Value = 12.35b USD (11.87b + Debt 1.68b - CCE 1.20b)
Interest Coverage Ratio = -106.1 (Ebit TTM -413.6m / Interest Expense TTM 3.90m)
EV/FCF = -55.94x (Enterprise Value 12.35b / FCF TTM -220.8m)
FCF Yield = -1.79% (FCF TTM -220.8m / Enterprise Value 12.35b)
FCF Margin = -22.48% (FCF TTM -220.8m / Revenue TTM 982.0m)
Net Margin = -42.39% (Net Income TTM -416.3m / Revenue TTM 982.0m)
Gross Margin = 64.46% ((Revenue TTM 982.0m - Cost of Revenue TTM 349.0m) / Revenue TTM)
Gross Margin QoQ = 64.63% (prev 64.71%)
Tobins Q-Ratio = 6.13 (Enterprise Value 12.35b / Total Assets 2.01b)
Interest Expense / Debt = 0.07% (Interest Expense 1.18m / Debt 1.68b)
Taxrate = 21.0% (US default 21%)
NOPAT = -326.8m (EBIT -413.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.84 (Total Current Assets 1.47b / Total Current Liabilities 302.7m)
Debt / Equity = -16.94 (negative equity) (Debt 1.68b / totalStockholderEquity, last quarter -99.3m)
Debt / EBITDA = -3.49 (negative EBITDA) (Net Debt 1.30b / EBITDA -373.9m)
Debt / FCF = -5.91 (negative FCF - burning cash) (Net Debt 1.30b / FCF TTM -220.8m)
Total Stockholder Equity = -252.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -23.79% (Net Income -416.3m / Total Assets 2.01b)
RoE = 164.9% (negative equity) (Net Income TTM -416.3m / Total Stockholder Equity -252.5m)
RoCE = -33.05% (EBIT -413.6m / Capital Employed (Equity -252.5m + L.T.Debt 1.50b))
RoIC = -34.04% (negative operating profit) (NOPAT -326.8m / Invested Capital 960.1m)
WACC = 8.84% (E(11.87b)/V(13.55b) * Re(10.08%) + D(1.68b)/V(13.55b) * Rd(0.07%) * (1-Tc(0.21)))
Discount Rate = 10.08% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 4.19%
[DCF] Fair Price = unknown (Cash Flow -220.8m)
EPS Correlation: 88.77 | EPS CAGR: 39.62% | SUE: 1.19 | # QB: 4
Revenue Correlation: 99.47 | Revenue CAGR: 33.16% | SUE: 0.95 | # QB: 7
EPS next Quarter (2026-06-30): EPS=-0.40 | Chg7d=+0.000 | Chg30d=-0.003 | Revisions Net=-2 | Analysts=16
EPS current Year (2026-12-31): EPS=-1.56 | Chg7d=+0.000 | Chg30d=-0.118 | Revisions Net=-6 | Growth EPS=+14.4% | Growth Revenue=+29.5%
EPS next Year (2027-12-31): EPS=-0.62 | Chg7d=+0.000 | Chg30d=-0.299 | Revisions Net=-3 | Growth EPS=+60.2% | Growth Revenue=+28.6%
[Analyst] Revisions Ratio: -0.25 (3 Up / 5 Down within 30d for Next Quarter)

Additional Sources for GH Stock

Fund Manager Positions: Dataroma | Stockcircle